Abstract: Packaging and a dessert food product combines a hot portion and a cold portion. In one embodiment, the dessert combines hot pie with a topping of ice cream in a single package. In one aspect of the invention, the microwaveable food product and package incorporates a food package that simultaneously includes various susceptor films that allow for differential heating of food. The susceptor film(s) shield the cold-portion food products from being heated in the microwave while they provide even heating of the hot portion of the product. The packaging provides a quick, convenient and tasty dessert with minimal effort. In another aspect of the present invention, the pie and ice cream formulation has been optimized to maintain superior flavor and texture properties after freezing and microwave reheating.

Abstract: A biodegradable injection moldable polymer having the composition a) from 50 to 85% by weight of a starch and or a modified high amylose starch b) from 4 to 13% by weight of a water soluble polymer selected from polyvinylacetate, polyvinyl alcohol and copolymers of ethylene and vinylalcohol which have a melting point compatible with the molten state of the starch components c) from 10 to 35% by weight of a polyol plasticizer d) from 0.5 to 10% of a polyethylene oxide or polyethylene glycol e) from 0 to 1.5% by weight of a C12-22 fatty acid or salt and f) from 0.25% to 3% of a food grade emulsifier. The polymers are suitable for biodegradable, flushable tampon applicators and other medical or industrial products where flushability and bio degradability are desirable.

Abstract: A wirelessly detectable tamper-evident seal (1) including a receptacle part (10) and a frangible part (50), the receptacle part (10) including a first receptacle (10a) and a second receptacle (10b-d) attachable to a container to seal a closure of the container and the frangible part (50) including a first portion (51) and a second portion (52) frangibly connected to each other, the first receptacle (10a) adapted to receive the first portion (51) and the second receptacle (10b-d) adapted to receive the second portion (52), the frangible part (50) including a transponder (54), the second portion (52) able to be trapped against movement in the reverse direction in the second receptacle (10b-d) to effect a tamper evident seal between the first and second receptacles (10a-d), wherein the transponder (54) includes at least two circuit interruption locations (94a, 94b) that must be connected to activate the transponder (54) and the transponder (54) is activatable by inserting the second portion (51) in the second re

Abstract: Packaging and a dessert food product combines a hot portion and a cold portion. In one embodiment, the dessert combines hot pie with a topping of ice cream in a single package. In one aspect of the invention, the microwaveable food product and package incorporates a food package that simultaneously includes various susceptor films that allow for differential heating of food. The susceptor film(s) shield the cold-portion food products from being heated in the microwave while they provide even heating of the hot portion of the product. The packaging provides a quick, convenient and tasty dessert with minimal effort. In another aspect of the present invention, the pie and ice cream formulation has been optimized to maintain superior flavor and texture properties after freezing and microwave reheating.

Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

Abstract: This invention relates to compounds of formula (I): wherein R1 is a branched or straight chain C1-C6 alkyl; R2 is of the formula (II), wherein n is an integer ranging from 1 to 8; R5 is H or (CH2)pCH3, and R6 is H or (CH2)mOH, wherein p is an integer ranging from 1 to 7 and m is an integer ranging from 1 to 8; R3 is of the formula (III), wherein q is an integer ranging from 1 to 8; and R7 is selected from the group consisting of H, OH, NH2, (CH2)tOH, and R9COOH; wherein R9 is a straight or branched chain alkylene or alkenylene group having 1 to 8 carbon atoms, and t is an integer ranging from 1 to 8; R4 is of the formula (IV), wherein r is an integer ranging from 1 to 8 and R8 is selected from the group consisting of H, OH, (CH2)fNH2, (CH2)sOH, and R10COOH; wherein f is 0 or f and s are independently integers ranging from 1 to 8; and, R10 is a C1-C8 straight or branched chain alkylene or alkenylene; and; salts, solvates, and hydrates thereof.

Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus. The present invention also relates to the use of the pyridyl heterocycles and hydro isomers thereof and/or pharmaceutical compositions comprising the compounds to treat or prevent HCV infections.

Abstract: Methods of controlling microbial growth utilizing thiazolium compounds are generally disclosed. Methods of controlling infestations relating to agricultural, industrial and marine uses through the use of thiazolium compounds are also disclosed. Further, methods of use of thiazolium compounds in medicine, particularly in the prophylaxis and treatment of inflammatory conditions, infectious conditions, as well as immune disorders are disclosed.

Abstract: wherein R3 is Alk14ArR16, and wherein Alk14 is C1-8 straight or branched alkylene or alkenylene. The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceutically acceptable carrier are further provided. Compositions also include diagnostic assay-type probes comprising a novel A1 adenosine receptor antagonist of formula (I) that is labeled or conjugated with radioactive or non-radioactive material. Methods for treating A1 adenosine receptor related disorders comprising administering an A1 adenosine receptor antagonist of formula (I) are also disclosed. The novel A1 adenosine receptor antagonist compositions of formula (I) find further use in diagnostic and imaging methods.

Abstract: This invention relates to compounds of formula (I): wherein R1 is a branched or straight chain C1-C6 alkyl; R2 is of the formula (II), wherein n is an integer ranging from 1 to 8; R5 is H or (CH2)pCH3, and R6 is H or (CH2)mOH, wherein p is an integer ranging from 1 to 7 and m is an integer ranging from 1 to 8; R3 is of the formula (III), wherein q is an integer ranging from 1 to 8; and R7 is selected from the group consisting of H, OH, NH2, (CH2)tOH, and R9COOH; wherein R9 is a straight or branched chain alkylene or alkenylene group having 1 to 8 carbon atoms, and t is an integer ranging from 1 to 8; R4 is of the formula (IV), wherein r is an integer ranging from 1 to 8 and R8 is selected from the group consisting of H, OH, (CH2)fNH2, (CH2)sOH, and R10COOH; wherein f is 0 or f and s are independently integers ranging from 1 to 8; and, R10 is a C1-C8 straight or branched chain alkylene or alkenylene; and; salts, solvates, and hydrates thereof.

Abstract: Methods and compositions for treating and preventing respiratory disorders are provided. The methods of the invention comprise administering to a subject a therapeutically effective amount of a pharmaceutically acceptable salt of an A1 adenosine receptor antagonist, particularly 1-hydroxy-2-naphthoic acid salts or 3-hydroxy-2-naphthoic acid salts, more particularly a 1-hydroxy-2-naphthoic acid salt of 3-[2-(4-aminophenyl)ethyl]-8-benzyl-7-{2-[ethyl-(2-hydroxyethyl)amino]ethyl}-1-propyl-3,7-dihydropurine-2,6-dione (i.e., an L-97-1 xinafoic acid salt). Hydrates of the A1 adenosine receptor antagonist salts described herein are further provided. The invention further encompasses pharmaceutical compositions comprising a pharmaceutically acceptable salt of an A1 adenosine receptor antagonist in a pharmaceutically acceptable carrier. The compositions of the invention find use in methods for treating and preventing respiratory disorders.

Abstract: Triazole derivatives and pharmaceutical compositions containing the derivatives are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the derivatives in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

Abstract: The present invention includes compounds of pyridinium salts and methods of their use for industrial uses. The present invention also relates to methods of controlling fungi and/or bacteria. The present invention may also be used to control insects.

Abstract: Compounds of the general formula (I) are described: wherein A is a 5- or 6-membered aromatic or heteroaromatic ring. Compositions comprising such compounds and methods of use thereof are also described.

Abstract: The present invention relates to pyridyl substituted heterocycles and hydro isomers thereof and pharmaceutical compositions thereof that inhibit replication and/or proliferation of HCV virus.

Abstract: The present invention provides compounds that are effective in treating central nervous system disorders and maintaining normal brain function. Methods of making and using the compounds are also provided.

Abstract: The present invention relates to substituted diphenyl heterocycle compounds and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compounds and/or compositions to inhibit HCV replication and/or proliferation and to treat or prevent HCV infections.

Abstract: A process for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts and solvates thereof such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via enzyme-catalyzed dynamic kinetic resolutions is provided.

Abstract: Disclosed is a method for preparing (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol, pharmaceutically acceptable salts, and pharmaceutically acceptable solvates thereof, such as the (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol hydrochloride salt via dynamic kinetic resolutions.